Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 May;53(5):1206-10.
doi: 10.1007/s10620-007-0009-9. Epub 2007 Oct 13.

Angiotensin II type 1 receptor antagonist suppress angiogenesis and growth of gastric cancer xenografts

Wei Huang  1 , Yun-Lin Wu, Jie Zhong, Feng-Xiang Jiang, Xiang-Long Tian, Li-Fen Yu
Affiliations

Angiotensin II type 1 receptor antagonist suppress angiogenesis and growth of gastric cancer xenografts

Wei Huang et al. Dig Dis Sci. 2008 May.

Abstract

Angiotensin II (Ang II) has been reported to promote tumor progression, tumor growth and angiogenesis in many cancers. We previously observed that angiotensin II type 1 receptors (AT1R) were upregulated in human gastric cancer and may be involved in the progression of gastric cancer. We studied the effects of AT1R antagonist on angiogenesis and growth in gastric cancer xenografts to observe the mechanism action of AT1R in the gastric cancer. The results showed that the growth of gastric cancer cells was significantly suppressed by treatment with AT1R antagonist. In vivo, TCV-116, at doses of both 2 and 5 mg/kg/day, significantly suppressed tumor growth in mice (47.3 and 70.2%). Microvessel density was significantly decreased by TCV-116 (3.4 +/- 0.9 and 2.8 +/- 0.5 per field) compared with the control group (12.9 +/- 1.1 per field), and VEGF expression was significantly suppressed by AT1R antagonist. These results demonstrate that AT1R plays an important role in the progression of gastric cancer. Suppression tumor angiogenesis could be one of the mechanisms by which AT1R antagonist suppresses the growth of gastric cancer. These findings also provide a theoretical basis for the future clinical application of AT1R antagonist against gastric cancer.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Expert Opin Biol Ther. 2006 Mar;6(3):243-55 - PubMed
    1. Br J Cancer. 1998 Mar;77(6):880-3 - PubMed
    1. Prostate. 2007 Jan 1;67(1):41-9 - PubMed
    1. Br J Cancer. 2006 Feb 27;94(4):552-60 - PubMed
    1. J Inflamm (Lond). 2004 Sep 30;1(1):3 - PubMed

MeSH terms

LinkOut - more resources